This project will combine data from European cohorts of persons with known dates of HIV seroconversion (seroconverters) to assess to what extent transmission with drug resistant HIV impacts on clinical outcome. The individual cohorts have been specifically set up as HIV natural history cohorts and study subjects are followed-up life-long from their initial contact with HIV. Although transmitted drug resistance has been documented, but may be under-estimated if data are not derived from seroconverters, its clinical importance has not been established. In studies of persons with known dates of seroconversion, the numbers included are often small and it is very difficult to draw conclusions, on whether a blunted immunology and virology response to therapy is more likely in someone newly infected with drug resistant virus than someone who is not.
Funding SchemeCON - Coordination of research actions
B9 5SS Birmingham
1018 WT Amsterdam
03550 San Juan De Alicante
W1T 4JF London